Pressure BioSciences, Inc. Provides Corporate Update
1) Phase I SBIR Grant Award: PBI was recently notified by the National Institute of Allergy and Infectious Diseases ("NIAID") of the NIH that it had been awarded a Phase I SBIR grant (1R43A1081518-01) for a total of
2) Presentation by Dr.
3) The Journal of Biomolecular Techniques Outstanding Manuscript Award: This annual award recognizes the best research article published each year in the journal. The 2009 award was recently presented to scientists from PBI and the
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical (primarily enzymatic) reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts in the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications.
Forward Looking Statements
Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include statements regarding the reported effectiveness of PCT in the extraction of proteins from cells and tissues, and the advantages of PCT in throughput and reproducibility; the adoption and growing acceptance of PCT over other sample preparation methods; the expectation that the Company's studies, when continued with the proceeds of the Phase I SBIR grant, will be successful, and may lead to the submission of a Phase II SBIR grant application in 2009, and the expected amount of such Phase II funding; the possibility that PCT products may be adopted by laboratories involved in the Human Microbiome Project and others working in the area of microbe detection and analysis; the Company's decision to focus primarily on the application of PCT-enhanced protein digestion for the mass spectrometry market and the advantages of PCT in this market; and the use of PCT in biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of PCT; changes in customer's needs and technological innovations; the Company's sales force may not be successful in selling the Company's PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods, particularly in the mass spectrometry market; and scientists may not be able to duplicate the results achieved at particular laboratories having already used PCT. Further, the Company expects that it will need additional capital to fund its continuing operations beyond the second quarter of 2010. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended
Visit us at our website http://www.pressurebiosciences.com/
Investor Contacts: Richard T. Schumacher, President & CEO R. Wayne Fritzsche, Chairman Pressure BioSciences, Inc. (508) 230-1828 (T)
SOURCE Pressure BioSciences, Inc.
More by this Source
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.